A new collaboration between UC Davis Health and Propeller Health will offer personalized treatment for high-risk patients with asthma and chronic obstructive pulmonary disease.
Avinash Sahu, PhD, and his team leveraged artificial intelligence, machine learning, and big data to create a novel way to discover multi-function drugs. The approach used cancer research data, biological data, and transfer learning to not only find drugs with specific properties but also to predict patient responses to them.
The members of the American Association for Cancer Research (AACR) have elected Patricia M. LoRusso, DO, PhD (hc), as the AACR President-Elect for 2023-2024. Dr. LoRusso will become President-Elect on Monday, April 17, during the AACR’s Annual Business Meeting of Members at the AACR Annual Meeting 2023 in Orlando, Florida. She will assume the Presidency in April 2024 at the AACR Annual Meeting in San Diego, California.
Human papillomaviruses (HPVs) cause several cancers in both men and women, including 91% of cervical cancers, 91% of anal cancers and 75% of vaginal cancers, according to the Centers for Disease Control and Prevention. Most of these cancers are caused by just a handful of HPV virus types.
A co-location model for cancer diagnostic services designed by researchers at Dana-Farber Cancer Institute has reported a reduction in the time it takes to diagnose cancer in a community health center in Boston, MA, that cares for a historically underserved populations.
20221027104337.jpg&width=400&height=400)
In 2012, Michael Cruz exercised a lot. Four years into a 15-year prison sentence, this was one of the only things he had, he says, until he noticed a numb, tingling sensation in one of his toes while working out. At first, he dismissed the feeling. But it persisted, and over time, spread up his ankle. Then, he began experiencing little sharp pains in his back, which he attributed to muscle spasms from his workouts.
Custom-made to attack cancer cells, CAR T-cell therapies have opened a new era in the treatment of human cancers, particularly, in hematologic malignancies. All too often, however, they display a frustrating trait inherited from the body's own immune system cells: a drastic loss of cancer-fighting fervor known as "exhaustion”.
More and more students are graduating with their bachelor's degrees and taking a gap year, a period of time before jumping into a postgraduate program. A new grant from the American Cancer Society will help the UNM Comprehensive Cancer Center introduce these students to scientific research.
Today, Yale Medicine physicians use a new form of technology called “robotic bronchoscopy,” which allows them to better reach smaller parts of the lungs. During a robotic bronchoscopy, the doctor uses a controller at a console to operate a robotic arm, which then guides the bronchoscope’s thin, flexible tube through the airways.
In a new paper published in Science, Dana-Farber Cancer Institute researchers outline the complexities of young-onset colorectal cancer and the research needed to map out a path toward understanding it.
In a Phase II trial led by researchers from The University of Texas MD Anderson Cancer Center, adding ipilimumab to a neoadjuvant, or pre-surgical, combination of nivolumab plus platinum-based chemotherapy, resulted in a major pathologic response (MPR) in half of all treated patients with early-stage, resectable non-small cell lung cancer (NSCLC).
In a new study published in the Journal of Clinical Oncology, Moffitt Cancer Center researchers report that a new smoking cessation intervention increased the number of patients who quit smoking compared to standard cessation approaches.
Lance Kawaguchi, an internationally recognized executive leader and board member with over 25 years of global finance and banking experience, will be undertaking a monumental Trek to the South Pole in December 2023 to raise funds for several charities, including the Cancer Research Institute (CRI). Serving as a strategic advisor, he has pledged to lead a global effort to raise awareness and funds for CRI.
MD Anderson announced Kerin Adelson, M.D., as the institution’s chief quality and value officer. Adelson is an accomplished clinician and researcher with extensive leadership experience in delivering high-quality and value-based cancer care.
Researchers from The University of Texas MD Anderson Cancer Center showed that inhibiting menin with revumenib, previously known as SNDX-5613, yielded encouraging responses for advanced acute leukemias with KMT2A rearrangements or mutant NPM1. Findings from the Phase I AUGMENT-101 trial were published today in Nature.
Memorial Sloan Kettering Cancer Center (MSK) has been recognized by the American College of Surgeons (ACS) for its commitment to providing optimal surgical care for children and adolescents.
In a new study published in Nature Medicine, Moffitt Cancer Center physician-scientists, in collaboration with four cancer centers in the United States and Germany, reveal how microorganisms in the gut influence non-Hodgkin lymphoma patient outcomes to a type of cellular immunotherapy called chimeric antigen receptor T-cell therapy, or CAR T.
With the arrival of March, Colorectal Cancer Awareness Month, faculty and staff in the Department of Internal Medicine’s Section of Digestive Diseases are redoubling their efforts to spread the word about the importance of screening, especially in younger individuals and those with a family history of the disease. Colorectal cancer is the second most common cause of cancer death in the United States.
The constant evolution of new COVID-19 variants makes it critical for clinicians to have multiple therapies in their arsenal for treating drug-resistant infections. Researchers have now discovered that a new class of oral drugs that acts directly on human cells can inhibit a diverse range of pathogenic SARS-CoV-2 strains. In their newly published study, the team found a novel mechanism through which the gene that expresses angiotensin converting enzyme-2 (ACE-2)—the cellular receptor to which SARS-CoV-2 binds so that it can enter and infect the cell—is turned on.
A first-of-its-kind study in the March 2023 issue of JNCCN highlights how the lack of genomic research for people with African ancestry, particularly those from the Sub-Saharan region, is hampering efforts to reduce disparities for people with advanced prostate cancer.
To assess the impact of hospitalist co-management, researchers compared real-time outcomes from both the co-management model and the traditional, oncologist-led inpatient services. They tracked patient volume, length of stay, early discharges, discharge time, and the rate of readmission within 30 days of discharge over a six-month span at Smilow Cancer Hospital in New Haven, Conn.
Dr. Marcus Bosenberg, an accomplished clinician, teacher, and researcher who studies the factors that regulate anti-cancer immune responses, was recently appointed the Anthony N. Brady Professor of Dermatology, Pathology, and Immunobiology, effective immediately.Bosenberg received his Ph.D. and M.D. at Cornell University Medical College.
A new class of oral drugs can inhibit a wide range of SARS-CoV-2 variants, researchers report, potentially identifying new antiviral agents providing broad activity against the constantly emerging new strains of the COVID-19 virus
In a new article published today in the Journal of Clinical Oncology, Moffitt Cancer Center physician-scientists, in collaboration with institutions from across the United States and the United Kingdom, share promising phase 1b trial results of a new combination therapy — magrolimab + azacitidine — for patients with higher-risk MDS.
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
A team of Yale scientists seeks to determine which treatment sequences produce the best results for people with advanced cancer while examining the cost of these treatments. The investigators recently received a four-year, $792,000 grant from the American Cancer Society to fund their studies. Shi-Yi Wang, associate professor of epidemiology (chronic diseases) at Yale School of Public Health (YSPH) is the principal investigator for the grant.
The intent of the new Consortium is to help increase access to early phase cancer clinical trials for patients who would otherwise not have the ability to be treated with novel investigational therapeutic interventions.
Differences in genes involved in inflammation, immunity response and neural transmissions begin in childhood and evolve across the lifespan in brains of people with autism, a UC Davis MIND Institute has found.
A team of researchers from institutions across the United States, including Moffitt Cancer Center, launched a phase 2 clinical trial evaluating a new treatment option for this patient population. Their results, published in The New England Journal of Medicine, show that treating resectable stage 3 and 4 melanoma patients with the immunotherapy drug pembrolizumab both before and after surgery greatly improves outcomes when compared to pembrolizumab given only after surgery.
Patients with high-risk melanoma who received the immunotherapy drug pembrolizumab both before and after surgery to remove cancerous tissue had a significantly lower risk of their cancer recurring than similar patients who received the drug only after surgery.
Dana-Farber is leading two studies to investigate novel treatment options for colorectal cancer patients. One study is looking at next-generation immunotherapy and the other is investigating CAR-T therapy in colorectal cancer.
NCCN 2023 Annual Conference featuring more than a thousand worldwide oncology professionals will present new research findings, latest NCCN Guidelines updates, and best practices for achieving quality cancer care delivery, in Orlando and online March 31—April 2, 2023. Visit NCCN.org/conference for more.
UC Davis researchers have been awarded $1.35 million from the Environmental Protection Agency to study the health impacts of wildfire smoke on pregnant people and children.
Expert from Rutgers Cancer Institute of New Jersey & RWJBarnabas Health discusses what young people should know about colorectal cancer as the disease continues to rise in those ranging in age from mid-20's to 50's.
UC Davis Health researchers have begun a new stem cell clinical trial to treat patients with swallowing problems. The study takes stem cells and injects them into the patient’s tongue.
23-year-old fundraiser for the UNM Comprehensive Cancer Center makes a comeback this spring.
The UNM Cancer Center will be one of a few sites in the country participating in a clinical trial to expand the application of theranostic treatment to patients with prostate cancer. This type of treatment is currently used at the cancer center for neuroendocrine tumors. The treatment is a two-part process that first injects the molecule attached to a gallium-68 radioactive isotope that can be imaged to illuminate the cancer cells, which makes them easier to see under Positron Emission Tomography, or PET scans.
Dario Marchetti, PhD, and his team at the UNM Comprehensive Cancer Center found the same common genomic signature in the circulating tumor cells taken from the mice and from the people with melanoma brain metastases. And they found this signature in the circulating tumor cells that were injected in the mice, as well as in cells isolated from a person with melanoma brain metastasis who was undergoing treatment.
Vaping cannabidiol (CBD), a compound found in marijuana, leads to more severe lung damage than vaping nicotine, according to a study out of Roswell Park Comprehensive Cancer Center. Until now, research on the health effects of vaping, or using e-cigarettes, has focused almost exclusively on vaping nicotine as opposed to CBD. Previous research has documented the effects of smoking cannabis, but the effects of vaping cannabinoids such as CBD were not previously known.
The National Comprehensive Cancer Network® (NCCN®)—a not-for-profit alliance of leading United States cancer centers—announces a new collaboration with the Institute of Hematology and Transfusion Medicine in Poland (IHIT), and the Alliance For Innovation—Polish-American Foundation (AFI).
The mural, designed in collaboration with members of organizations in the surrounding urban community, is one part of the The University of Kansas Cancer Center’s broader campaign to increase the participation of minority and underserved populations in clinical trials.
A Yale-led study examines the potential environmental benefits of more carefully selecting patients for prostate biopsy in a way that can also spare low-yield and potentially harmful procedures
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back. Recent developments include a new understanding of how HPV drives cancer development, a combination therapy to overcome treatment resistance in mantle cell lymphoma, novel insights into memory T cell formation and potential therapeutic strategies for brain cancers, improved survival outcomes for metastatic colorectal cancer, targeting myeloperoxidase to improve immunotherapy responses in melanoma, and preclinical results of a combination therapy that could effectively treat a subset of acute myeloid leukemia.
Patients with early-stage estrogen receptor-positive breast cancer who live in low-income neighborhoods are likelier to have more-aggressive tumors and significantly lower overall survival (OS) than those in higher-income neighborhoods, according to research led by Roswell Park Comprehensive Cancer Center. The study, “Association of neighborhood-level household income with 21-gene recurrence score and survival among patients with estrogen receptor-positive breast cancer,” appears today in JAMA Network Open.
This study shows vaccination against COVID-19 is an essential strategy to improve outcomes in this high-risk population. The results support guidelines that patients with cancer should receive at least 3 COVID-19 vaccine doses.
Early diagnosis of uterine cancer is known to improve a patient’s chances for survival, but previous research has found that Black patients are less likely to receive early diagnoses than people of other racial and ethnic groups. A new analysis by Yale researchers provides insights into why that is: They found that Black patients were more likely than their white counterparts to experience testing delays or to not receive recommended tests at all.
The University of Texas MD Anderson Cancer Center today was awarded 15 grants totaling $19.38 million from the Cancer Prevention and Research Institute of Texas (CPRIT) in support of cancer research projects across the institution.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right
